Skip to main content
. 2017 May 9;19(11):1481–1493. doi: 10.1093/neuonc/nox052

Fig. 3.

Fig. 3

Western blot analysis of MEK ± PI3K inhibitor treatment in MDA-MB-231Br. (A) Immunoblots of phosphorylated (p-) and total ERK, Akt, and MEK in control, selumetinib, buparlisib, combination (“combo”) daily, and combo 5-2 treated tumors, n = 4 per group. Quantitation of (B) pERK to total ERK, (C) pAkt to Akt, and (D) pMEK to MEK levels by densitometry of immunoblot bands from (A). Overall P shown; *pairwise vs control P ≤ 0.05.